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Abstract 
 
Background 
Depression is common in dementia causing considerable distress, and other negative 
impacts. Treating it is a clinical priority but the evidence base is sparse and equivocal. 
 
Methods 
The HTA-SADD (study of the use of antidepressants for depression in dementia) trial 
was a multi-centre parallel group double-blind placebo-controlled pragmatic RCT of the 
clinical effectiveness of sertraline and mirtazapine (primary outcome 13 weeks; long 
term 39 weeks). Eligibility: probable or possible Alzheimer's Disease, depression (4+ 
weeks), and Cornell Scale for Depression in Dementia (CSDD) score of 8+, from 9 
English old age psychiatry services. Exclusions: clinically too critical (eg suicide risk); 
contra-indication to medication; taking antidepressants; in another trial; and having no 
carer. Interventions: (1) sertraline, (2) mirtazapine, and (3) placebo, all with normal care. 
Target doses: 150mg sertraline or 45mg mirtazapine daily. The objective was to 
determine clinical effectiveness of sertraline and mirtazapine in reducing depression 13 
weeks post-randomisation compared with placebo. The main outcome was CSDD score. 
Randomisation: 1:1:1 allocation with stratified computer-generated block randomisation 
by centre with randomly varying block sizes by a Trials Unit, independent of trial team. 
Medication and placebo were identical for each antidepressant. Referring clinicians, 
research workers, participants, pharmacies and statisticians were blinded until analyses 
were completed. 
 
Findings 
326 participants were randomised (111 placebo, 107 sertraline, 108 mirtazapine). The 
main outcome, mean differences (95%CI) in CSDD at 13 weeks from an adjusted linear 
mixed model were: placebo/sertraline 1.17 (-0.23 to 2.58, p=0.10); placebo/mirtazapine 
0.01 (-1.37 to 1.38, p=0.99); and mirtazapine/sertraline 1.16 (-0.25 to 2.57, p=0.11). 
There were no statistically significant differences in depression score between groups at 
13 or 39 weeks. The placebo group had fewer adverse reactions (29/111, 26%) than 
sertraline (46/107, 43%) or mirtazapine (44/108, 41%; p=0.017) and fewer serious 
adverse events rated as severe (p=0.003).  39 week mortality was equal with five deaths 
in each group. 
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Interpretation  
This is a trial with negative findings but important clinical implications. The data suggest 
that the antidepressants tested, given with normal care, are not clinically effective 
(compared with placebo) for clinically significant depression in Alzheimer’s disease and 
there are harms associated with their use. This implies a need to change current 
practice of antidepressants being the first line treatment of depression in Alzheimer’s 
disease.  EudraCT Number - 2006-000105-38 
 
Funding 
This independent trial was funded by the UK National Institute of Health Research 
Health Technology Assessment Programme. 
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Introduction 
 
Background  
Dementia is a severe and challenging public health issue, affecting 35 million worldwide 
(trebling by 2050);1 costing $600 billion annually; 1% of world GDP.2 Dementia has a 
devastating impact on those affected and their family carers across culture, gender, 
ethnicity and class. Depression is common in dementia with prevalence over 20%,3,4 
causing distress, reducing quality of life,5 exacerbating cognitive and functional 
impairment,6 increasing mortality,3 and increasing carer stress and depression.7  
 
Treating depression in people with dementia is a clinical priority but the evidence base is 
sparse and equivocal. The most recent Cochrane review8 identified six relevant studies; 
only three could be meta-analysed. The first two studied the tricyclic antidepressants 
(TCAs) clomipramine9 (n=24) and imipramine10 (n=61), and the third, DIADS11,12 (n=44,) 
sertraline a specific serotonin reuptake inhibitor (SSRI).13 Findings of the first were 
balanced, the second negative and the third positive. The review concluded there was 
only weak evidence of the effectiveness of antidepressants in dementia. Two studies 
used TCAs “drugs not commonly used in this population” due to anticholinergic side 
effects; only one used the most commonly used class (SSRIs). None covered newer 
classes of antidepressants and all were of short duration. One further relevant 
randomised controlled trial (RCT) has been published since. DIADS-2, compared 67 
people prescribed sertraline with 64 given placebo; in contrast to DIADS, they found no 
benefit of sertraline at 12 or 24 weeks.14,15 A recent systematic review and meta-analysis 
including these data (total n=330)16 confirmed the evidence base as equivocal with larger 
definitive trials needed.  
 
Despite this, current practice is to use antidepressants, often sertraline, as a first line 
treatment for depression in dementia. The Quality Standards Subcommittee of the 
American Academy of Neurology17 concluded “SSRIs may offer some benefit”. A UK 
guideline suggests antidepressants as the only form of management for depression in 
dementia18 and the UK NICE/SCIE Clinical Guideline on Dementia19 advocates their use. 
Given uncertainty in this clinically important area, the UK NIHR commissioned this study 
to fill gaps in the evidence base definitively..  
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Objectives To determine the clinical effectiveness of an SSRI (sertraline) and a 
Noradrenergic and Specific Serotonergic Antidepressant (NASSA, mirtazapine) in 
reducing depression (measured by CSDD) 13 weeks post randomisation compared with 
placebo. Secondary objectives included: clinical effectiveness at 39 weeks; differences 
in harm; other outcomes (quality of life, cognition, carer burden, carer quality of life, 
death); and the influence of clinical characteristics (dementia severity, dementia type, 
depression type, depression severity, and neuropsychiatric symptoms). Cost data and 
analyses will be presented elsewhere. 
 
 
Methods 
 
Trial design 
Multi-centre parallel group double-blind placebo-controlled RCT of the clinical 
effectiveness of two antidepressants with 13 and 39 week follow up (1:1:1 allocation). 
Ethical approval: North West 7 (Greater Manchester) Ethics Committee. Full trial 
protocol:http://www.iop.kcl.ac.uk/projects/?id=10287. 
 
Participants  
Eligibility - A pragmatic trial, with inclusion criteria mirroring clinical practice. All met 
NINCDS/ADRDA criteria for probable or possible Alzheimer's Disease20 (ascertained by 
referring psychiatrist) and co-existing depression (4+ weeks duration) assessed as 
potentially needing antidepressants. A research worker then assessed depression 
severity using the CSDD,13 those scoring 8+ were eligible. All research workers were 
trained in the assessments including the CSDD in group sessions at seven meetings 
through the trial plus individual training sessions with the trial manager. All recruited 
between the meetings were trained by the trial manager and local top-up training was 
provided whenever necessary. As well as initial CSDD training sessions, meetings 
featured refreshers, with scoring exercises showing good reliability between raters. The 
only exclusions were: clinically too critical for randomisation (eg suicide risk); absolute 
contra-indication to trial medications; currently taking antidepressants; being in another 
trial; and having no family or professional carer informant. Participants were recruited 
from old age psychiatry services in nine English centres (Birmingham, Cambridge, 
Leicester, Liverpool, Manchester, Newcastle, North London, Southampton, and South 
London & Kent). 
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Interventions  
Three groups: (1) sertraline, (2) mirtazapine, and (3) placebo, all with normal clinical 
care. The target doses were 150mg sertraline or 45mg mirtazapine daily. Drugs and 
their placebo were identically presented with participants aiming to take six tablets orally 
once a day (up to three sertraline 50mgs or sertraline placebo; and up to three 
mirtazapine 15mgs or mirtazapine placebo). The participants started on one of each 
tablet. They were told to increase the dose to two of each at two weeks. At four weeks 
the research worker telephoned and completed a CSDD. If the score was 4 or more then 
the dose was increased to the target dose of three of each tablet. If the score was below 
4 at week 4 they stayed on two of each and were contacted at week 8 when, if their 
CSDD was 4 or more the dose was increased to three of each tablet. Thereafter it was 
open to clinicians to adjust the dose. 
 
Outcomes 
Co-primary outcomes – Depression in dementia, CSDD,13 and costs Client Service 
Receipt Inventory (CSRI)21 at 13 weeks. Cost data will be reported elsewhere.  
 
Secondary outcomes and moderators - disease-specific health related quality of life 
(DEMQOL and DEMQOL-Proxy);22 generic quality of life (EQ-5D interview administered 
to carer);23 withdrawal from treatment; cognition (Mini Mental State Examination 
MMSE);24 depression severity (CSDD score low 8-11, high 12+); depression type 
(depression in Alzheimer’s disease by Olin criteria25); medication adherence; adverse 
events; carer mental health (General Health Questionnaire GHQ-12)26; carer quality of 
life (SF-12v2);27 carer burden (Zarit);28 behavioural disorder (Neuropsychiatric Inventory 
NPI);29 and baseline dementia vascularity index (modified Hachinski).30 
 
Sample size 
Initially a sample size of 507 was calculated to provide 90% power to detect a 2 point 
CSDD difference (standard deviation [sd] 5; Standardised Effect Size [SES] 0.4) for 13 
week sertraline/placebo and mirtazapine/placebo comparisons, and 86% power at 39 
weeks. This allowed 20% loss to follow-up and CSDD baseline/outcome correlation ≥ 
0.6 using analysis of covariance with two sided 5% significance levels and two sided 
95% confidence intervals (95%CI) for a (clinically significant) 10% difference in adverse 
events between groups. 
 7 
 
Change to protocol – Due to a call for extra funding following slower recruitment than 
predicted, the sample size needed for the trial was statistically reviewed by the Data 
Monitoring and Ethics committee when there were 75 subjects with 13 week follow-up 
data. The parameters of the sample size calculation were not changed (sd 5; SES 0.4). 
The new target was based on observed values which gave greater precision than the 
pre-study assumptions. An extended recruitment period was agreed with a revised target 
of 339 for the sample (113 in each group). This involved unblinding a statistician to the 
identity of the placebo group; that statistician was not involved in the final analyses. 
 
Randomisation 
Participants were allocated to placebo, sertraline or mirtazapine (1:1:1) through the 
Clinical Trials Unit (CTU) after baseline assessment and consent. The CTU 
independently undertook treatment allocation. Allocation was by centre using stratified 
block randomisation with randomly varying block sizes and computer-generated 
randomisation. Allocation was carried out during working hours Monday to Friday 
 
Blinding 
The trial was double-blind with medication and placebo identical in appearance for each 
antidepressant. Referring clinicians and research workers completing baseline and 
follow-up assessments were kept blind to group allocation as were patients and 
pharmacies. Statisticians were blind to group identity until analyses were complete. 
 
Statistical methods 
The statistical analysis plan was finalised and approved by the Trial Steering and the 
Data Monitoring and Ethics Committees. Significance was tested at 5% level for all 
analyses. Analyses were completed in STATA 11.0. Analyses were pragmatic, based an 
intention to treat sample. Continuous variables were summarised with mean and sd, 
categorical variables were summarised using frequency and percentages. The primary 
analyses, CSDD differences between treatment groups (sertraline/placebo and 
mirtazapine/placebo), were estimated with mixed linear regression models31. Covariates 
were treatment, baseline CSDD, time and the stratification factor, centre. A time-by-
treatment interaction term was included to allow estimates at the individual time points to 
be summarised. The model for the CSDD incorporated random intercepts by participant. 
Model assumptions were checked using diagnostic plots. Modelling was based on the 
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assumption that data were missing at random and predictors of missing data (treatment 
group and centre) were included in the modelling. A logistic model was used to assess 
predictors of missing data (examining all baseline clinical and demographic variables). 
Categorical variables were compared using Fisher’s Exact test. Secondary outcomes 
were analysed using mixed linear regression models with random participant intercepts 
and a time-by-treatment interaction term, covariates in the model were treatment group, 
baseline value of outcome, time and centre. Results from all analyses were summarised 
at 13 and 39 weeks with 2 sided 95%CIs. 
 
Role of the funding source 
The funder of the study had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. All named authors had access to data, commented 
on drafts, and approved the final report. SB had final responsibility for the decision to 
submit for publication. 
 
 
Results 
 
Participant flow 
Participant flow is presented in Figure 1. By week 39, 27 (24%) had withdrawn from 
placebo, 37 (35%) from sertraline and 31 (29%) from mirtazapine. Dropouts were not 
statistically significantly different between groups (Fisher’s exact test, p=0.26). 
 
Recruitment  
326 participants were recruited into the study between January 2007 and December 
2009; follow-up interviews were completed by October 2010.   
 
Baseline data 
Baseline demographic and clinical characteristics by group are presented for participants 
and carers in Tables 1 and 2 respectively. There were no differences between the 
randomisation groups. 
 
Numbers analyzed 
111 participants were randomised to placebo, 107 to sertraline, and 108 to mirtazapine. 
The number of participants included in each analysis is indicated in the tables. The 
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overall mean dosages (including those who withdrew from medication) taken were 70mg 
of sertraline and 24mg of mirtazapine. For those who remained on prescribed 
medication the mean dosage was 95mg sertraline and 30mg of mirtazapine. 
 
Outcomes and estimation 
Severity of depression (CSDD score), decreased in all three intervention groups 
compared with baseline. The greatest absolute improvement at the primary endpoint (13 
weeks) was with placebo -5.6 (sd 4.7) compared to -3.9 (sd 5.1) with sertraline and -5.0 
(sd 4.9) with mirtazapine. At 39 weeks recovery from baseline was sustained in all 
groups with change score of -4.8 (sd 5.5) for placebo, -4.0 (sd 5.2) for sertraline and -5.0 
(sd 6.1) for mirtazapine. Changes in CSDD score over the trial period are summarised in 
Figure 2.  
 
The result of the linear mixed modelling, adjusting for baseline depression severity and 
centre are presented in Table 3. In terms of the primary outcome, there were no 
statistically significant differences between either sertraline or mirtazapine and placebo 
or between sertraline and mirtazapine. These analyses provide robust evidence of a lack 
of clinical effectiveness of the antidepressants tested here compared with placebo.  
 
The effectiveness of the medications compared with placebo and between themselves 
on secondary participant outcomes are presented in Table 4. Again there is little change 
attributable to the antidepressants. The only statistically significant associations 
observed were at week 13 where fewer neuropsychiatric symptoms and higher carer-
rated participant health related quality of life (DEMQOL-Proxy) were observed in the 
mirtazapine group compared with sertraline. These differences did not persist at 39 
weeks . 
 
There was no change in the findings when subgroup analyses were completed 
examining outcomes by different baseline depression severity (CSDD score 8-11 v 12+). 
All but 8 participants (1 placebo, 3 sertraline, 4 mirtazapine) met criteria for categorical 
diagnosis of depression in Alzheimer’s disease using “Olin criteria” Sensitivity analyses 
with the Olin criteria as a moderator were not appropriate, due to the very low frequency 
of Olin criteria non-caseness. However this gives reassurance of the clinical significance 
of the depression in dementia investigated here. 
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Examining carer outcomes at 13 weeks, those whose relative was receiving placebo had 
higher quality of life (SF-12 Mental Component Score) and better mental health (GHQ-
12) than those on sertraline. Finally there was higher quality of life (SF-12 Mental 
Component Score) at 13 weeks in the carers of the mirtazapine group compared with 
the carers of the sertraline group. These differences did not persist at 39 weeks . 
 
Harms 
Adverse reactions to week 39 are presented in Table 5. The placebo group had a lower 
overall rate of adverse reactions (29/111, 26%) compared with sertraline (46/107, 43%) 
and mirtazapine (44/108, 41%); this difference was statistically significant (Fisher’s Exact 
test, p=0.017). The pattern was different between groups with gastrointestinal reactions 
more common with sertraline (most commonly nausea) and psychological reactions 
more common with mirtazapine (most commonly drowsiness and sedation). Examining 
severity, at 13 weeks, there were 15 serious adverse events in the placebo group of 
which 3 (20%) were rated severe; 12 in the sertraline group (8 [67%] severe) and 14 (10 
[71%]) severe) in the mirtazapine group. Overall there was no statistically significant 
difference in the number of serious adverse events reported but more of these were 
severe in those on antidepressants compared with placebo (Fisher’s Exact test, 
p=0.003). There was no difference in mortality between the three groups with five deaths 
in each at 39 weeks. 
 
 
Discussion 
 
This is a trial with negative findings but important clinical implications. The data suggest 
clearly that antidepressants, given with normal care, are not clinically effective when 
compared with placebo for the treatment of clinically significant depression in dementia. 
This implies a need to change the current clinical practice of prescribing antidepressants 
as the first line treatment of depression in dementia due to Alzheimer’s disease.   
 
Limitations 
First, drop out will introduce bias if those lost have a different response to the 
interventions or placebo compared with those completing the trial. However this was a 
pragmatic trial with few exclusions to mirror real clinical populations and levels of 
disengagement similar to those in clinical settings. Strenuous efforts were made to follow 
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up and obtain outcome data on all randomised who defaulted from either the trial 
compound or services.   
 
A second possible limitation is the revision during the trial of the target sample size. 
However, the new target was set using the same parameters as the pre-study 
calculations. We recruited 326/339, falling short by 13. Nevertheless, this is the largest 
ever RCT of depression in dementia with unequivocal findings showing no effect of 
either antidepressant compared with placebo. Had the pattern of change seen in those 
recruited been continued, the extra precision in estimates from either another 13 cases, 
or even achieving the original 507, would not have generated a statistically significant 
positive result for either antidepressant.  
 
Third, measurement error caused by cognitive impairment is a potential limitation. 
However the study included only measures well validated for use in dementia. Our 
primary outcome, the CSDD, is the most robust available measure of depression in 
dementia,32 incorporating data from the carer, the person with dementia, and the rater.  
 
Finally, we did not capture elements of intervention by clinical teams. Had we been able 
to characterise non-drug elements of treatment, we might have been able to investigate 
their role in patient recovery. However randomisation means these were distributed 
equally across the three groups, so results would not have changed.  
 
Generalisability 
This study was designed to reflect real clinical populations and interventions closely. We 
minimised exclusions and had permissive inclusion criteria. However the findings will not 
apply to those too critically ill to risk randomisation (chiefly those with high suicide risk). 
Only three potential participants were excluded on this criterion but there will have been 
more not referred into the trial. Equally, outcomes of those with depression but a CSDD 
score under 8 would not be covered. However very few people with a CSDD score at 
this level would have clinically significant depression, so impact on generalisability will 
be limited. 
 
Study strengths include its size and the broad nature of the study group, both by severity 
of depression and dementia, neither of which appeared to influence outcomes. We 
included not just narrowly defined Alzheimer’s disease but also those with probable and 
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possible Alzheimer’s. This is closer to populations encountered in clinical practice where 
there is often mixed dementia (with a vascular component to dementia). However 
prudence would limit generalisation to Alzheimer’s disease and mixed dementia and not 
other subtypes (vascular dementia, dementia with Lewy bodies or fronto-temporal 
dementia).  
 
One limit to generalisability comes from cases being drawn from old age psychiatry 
services. Such services are designed to deal with complex clinical situations, however 
some people with depression in dementia are not referred to specialist services but 
remain either treated or untreated in primary care. Possibly, such cases would respond 
differently to antidepressants. However, finding unrecognised, untreated cases in 
primary care is difficult and referral of such cases to specialist services is good practice. 
Since participants were not drawn from specialist research clinics or tertiary care, but 
from nine geographically diverse areas with a large number of clinicians representative 
of services in general (please see acknowledgements), the external validity of the results 
here will be maximised.   
 
The drugs used in this study represent the two most used classes of antidepressants but 
whether other classes (eg dual-acting antidepressants like venlafaxine) might have an 
effect is unclear; it would however be reasonable to expect broadly similar responses in 
drugs of the same class. 
 
Interpretation 
The main message from this study is that the drugs from the two classes of 
antidepressants most likely to be prescribed for depression in Alzheimer’s disease 
appear to be no more effective than placebo. It is however encouraging for people with 
depression in dementia that there was a strong consistent pattern of improvement in the 
depression at three and nine month follow up for this group of people referred to old age 
psychiatric services. This study gives strong evidence that this improvement is not 
attributable to antidepressants. What this study cannot tell us is if this improvement is a 
function of the non-drug “treatment as usual” by these old age psychiatric services, or 
due to artefact such as regression to the mean, the Hawthorne effect, or part of the 
natural history of depression in dementia. The last is perhaps made less likely by the 
finding that 221/326 (68%) had been depressed for more than six months prior to 
randomisation. 
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In terms of harms from medication, there were more adverse reactions in those on 
antidepressants compared with placebo as in other studies.14,15 It is important to be 
cautious about conclusions from analyses of secondary outcomes; the key message 
remains that there is no positive effect of the antidepressants on any pre-specified 
comparison with placebo. There is however a signal in the data consistent with the 
pattern of adverse reactions observed. There were fewer neuropsychiatric symptoms, 
higher carer-rated participant quality of life, and higher carer quality of life in those 
treated with mirtazapine compared with sertraline. Also, carers of those receiving 
placebo had higher quality of life themselves and better mental health compared with 
those caring for people on sertraline. Taken together, even though these differences did 
not persist at 39 week follow-up, they may suggest that sertraline has more negative 
impacts than mirtazapine. This is of clinical importance since it has become common 
clinical practice to use sertraline following the positive results of the first DIADS study.12 
 
So what can be concluded? The data suggest that antidepressants should not be 
prescribed as a first line treatment for people with depression in Alzheimer’s disease 
who are referred to old age psychiatry services as many cases will resolve with usual 
care, without sertraline or mirtazapine. Stepped care, with ‘watchful waiting’ is advocated 
for the community treatment of depression (without dementia). The first step being “low-
intensity psychosocial interventions” with more complex psychosocial interventions an 
alternative to antidepressants at the next stage of severity.33  Those recruited into the 
trial benefitted from the non-drug ‘treatment as usual’ provided by the community mental 
health teams to whom they were referred. This will have included a broad range of 
supportive and problem-solving interventions, commonly delivered by a community 
psychiatric nurse, often in their own household. This will have focussed on problems 
encountered by the person with dementia and the carer, covering aspects of dementia 
as well depression and ranging in intensity from low to high as needed. Identifying which 
components of ‘usual care’ may be effective is an important area for future research. 
Compared with this personalised care the Hawthorne effect of the study assessments is 
likely to have had only a minor impact. These data suggest that having depression in 
dementia may be an appropriate trigger for referral to specialist services where non-drug 
treatments can be deployed, perhaps avoiding the use of medication with potential for 
adverse reactions. 
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As in the DIADS-2 study, the lack of response of depression to antidepressants 
observed here do not seem to be attributable to low depression severity, the type of 
depression recruited or to low medication compliance.. This suggests that depression in 
dementia may be different in terms of neurobiology than depression occurring in those 
without dementia. Diagnosing depression in dementia can be complicated. This study  
provides support for the need for accurate specialist diagnosis and management of 
dementia and co-morbidities34 given that establishing such services has been shown to 
be feasibile35 and cost effective.36 
  
In summary, the practical implications of this study are that we should reframe the way 
we think about the treatment of people with dementia who are depressed, with the 
routine prescription of antidepressants reconsidered. Where potential cases are 
recognised these should be referred to local specialist services. Based on the data (a 
decrease in depression at 13 weeks with this then maintained), the use of 
antidepressants might be reserved for those whose depression has not resolved within 
three months of referral, except for those in whom medication is indicated by risk or 
extreme severity.  
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Keogh; Cambridge - Angela Lynch, Kathryn Betts, Jane Addison, Fiona McDougal, 
Angela Browne, Regina Mello-Barreto, Freya Mellor; Leicester - Sarah Baillon, Penny 
Wakefield, Alex Satchwell, Anne Chafer, Tracy McCranor, Rumun Sandhu, Shaukat 
Desai; Liverpool - Lisa Douglas, Helen Newell, Samantha Fitzpatrick, Rachel Whalley, 
Leann Westmoreland, Maggie Lo, Caroline Mogan, Helen Beaumont-Kellner; 
Manchester - Jackie Crowther, Stephen Chew-Graham, Octavia Smart, Emma Oughton, 
Jonathan Bowker, Katrina Wade, Ann Morrow, Gemma Woods, Helen Williams, Maria 
Kaltsi, Magdalen Fiddler, Nichola Verstraelen, Rebecca Rowles, Lindsey Copeland; 
Newcastle - June Pearson, Jill Davison, Suzanne Humphrey, Joshua Wood, Saffra 
Knox, Jessica McClosky, Katherine Richardson, Karen Anne Morgan, Vanessa Waggott; 
North London - Ryan Li, Sharmila Logathas, Stephanie Habermann, Kofi Kramo, Shilpa 
Bavishi, Patricia Ndhlovu, Sarah Dickens, Khodayar Shahriyarmolki, Emily Dixon, Maria 
Sampson, Gemma Hardy, Bertha Mangunda; Southampton -,Christine Dean, Annette 
Stevens, Laura Wolfe; South London & Kent – Michaela Poppe, Thandy Mtendera, Gaby 
Illingworth, Sue Thompson, Mohamed Pujeh, Alex Quigley. CTU team - Joanna Kelly, 
Caroline Murphy, Clare Rutterford, Rajesh Shah. 
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Panel 
 
Research in context 
 
Systematic review 
We searched PubMed and Cochrane Library databases up to 1 March  2011, without 
language restrictions for full papers reporting randomised controlled trials, systematic 
reviews, and meta-analyses with the search terms “depression”, “dementia”, 
“Alzheimer’s disease”, antidepressant”, ”meta-analysis” and “CSDD”. We excluded trials 
of where there was no recognised depression outcome measure, where there was no 
placebo, and where no threshold for depressive disorder was specified. We identified the 
most recent Cochrane Review8 and three further more recent systematic reviews.16,37,38 
In terms of meta-analysis, the Cochrane review identified three studies (107 subjects) 
where data that could be combined. Results were negative for Hamilton scores (4 
studies, n=128) mean effect size -0.93 [95%CI -3.27, 1.41], but positive for CSDD (1 
study n=44) -6.7 [-11.5 to -1.90], though this was from just one study. They concluded 
that there was only weak evidence available of the effectiveness of antidepressants in 
dementia. The 2007 study,35 using different quality assessment, included data from 5 
studies (165 subjects) and concluded that antidepressants were superior to placebo for 
both treatment response (odds ratio [OR] 2.32; 95% confidence interval [CI], 1.04 to 
5.16) and remission of depression (OR 2.75; 95% CI, 1.13 to 6.65) with rates of 
discontinuation comparable to placebo. One subsequent trial14,15 found no positive effect 
of sertraline at 3 and six months. The meta-analysis of the 2010 systematic review34 is 
questionable because, although it includes this most recent trial, it appears that it might 
count the data from the first DIADS trial twice, using both the interim and the final trial 
data. Finally the 2011 study concluded that the efficacy of antidepressants in people with 
depression and dementia is not established. The reviews and meta-analyses taken 
together are non-conclusive but all reported that limitations of previous trials included 
small size, few using drugs that were used in clinical practice and short term follow-up. 
  
Interpretation 
The two classes of antidepressants most likely to be prescribed for depression in 
Alzheimer’s disease appear to be no more effective than placebo. In terms of harms 
from medication, there were more adverse reactions in those treated with 
antidepressants compared with placebo. The practical implications of this study are that 
we should reframe the way we think about the treatment of people with Alzheimer’s 
disease who are depressed, with the routine prescription of antidepressants 
reconsidered. 
 
Ethics  
This study was approved by the North West 7 (Greater Manchester) Ethics Committee. 
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Figure1: Trial participant flow (Consort diagram) 
 
Referred to RW as 
Potentially Eligible
(n = 664 )
Excluded from Trial (n = 338)
Primary Eligibility Reason (n = 42)
       No clinical diagnosis of mild/moderate probable/possible AD (n = 2)
       No depressive illness needing antidepressant treatment (n = 10)
       Depression duration less than 4 weeks at referral (n = 0)
       Currently prescribed antidepressant medication (n = 2)
       Severe dementia (MMSE<8) (n = 1)
       Case considered too critical to be randomised (n = 3)
       Display absolute contraindications to the trial interventions (n = 2)
       In another trial (n = 1)
       No identifiable family carer or other informant (n = 3)
       Mild depression (CSDD<8 at randomisation) (n = 18) 
 Primary Consent Reason (n = 289) 
       Carer/Informant declined (n = 101)
       Patient declined (n = 207)
       Carer declined collateral information (n = 51)
       Local clinician declined (n = 9)
       Other ( n = 11)
Reason for Exclusion not recorded (n = 13)
Randomised 
1:1:1
(N = 326)
Placebo
Withdrawn from treatment 
before 13 week assessment:
(n=24)
Withdrawn from trial before 
13 week assessment:  (n=14)
CSDD at week 13: (n= 97)
Placebo
Withdrawn from treatment 
between 13 and 39 week 
assessment: (n =18)
Withdrawn from trial between 13 
and 39 week assessment:
(n = 13)
CSDD at week 39: (n=84)
Placebo
(n =111)
Mirtazapine
(n = 108)
Sertraline
(n=107)
Sertraline
Withdrawn from treatment 
before 13 week assessment:
(n=29)
Withdrawn from trial before 
13 week assessment:  (n=28)
CSDD at week 13: (n= 78)
Sertraline 
Withdrawn from treatment 
between 13 and 39 week 
assessment: (n =11)
Withdrawn from trial between 13 
and 39 week assessment: (n = 
9)
CSDD at week 39: (n=69)
Mirtazapine
Withdrawn from treatment 
before 13 week assessment:
(n=24)
Withdrawn from trial before 
13 week assessment:  (n=20)
CSDD at week 13: (n= 88)
Mirtazapine
Withdrawn from treatment 
between 13 and 39 week 
assessment: (n =16 )
Withdrawn from trial between 13 
and 39 week assessment: (n 
=11)
CSDD at week 39: (n=77)
 
 
 
Notes: 
Withdrawal from treatment implies the participant remains in the trial.  
Withdrawal from the trial implies the participant withdraws from the trial and from treatment.  
These two categories of withdrawal are mutually exclusive. 
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Table 1: Summary of participant and carer demographics and characteristics at baseline 
Data are mean (sd) or number (%) unless stated otherwise 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Placebo 
N= 111 
Sertraline 
N= 107 
Mirtazapine 
N= 108 
Participant     
Age (years)  79 (8.8) 80 (8.4) 79 (8.4) 
Sex (Male) 40 (36%) 34 (32%) 31 (29%) 
Ethnicity (White)  104 (93%) 98 (92%) 101 (94%) 
Marital status (Married) 48 (43%) 51 (48%) 60 (56%) 
Residence (lives in care home) 20 (18%) 13 (13%) 17 (16%) 
    
Carer  N= 151 N=123 N=139 
Age (years) 59 (14.8) 61 (13.9) 61 (17.1) 
Sex (male) 46 (31%) 37 (30%) 48 (35%) 
Ethnicity (White) 119 (79%) 109 (90%) 119 (86%) 
Martial status (married)  93 (61%) 82 (77%) 85 (79%) 
Relationship to participant (paid 
carer) 
40 (26%) 19 (16%) 34 (25%) 
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Table 2: Summary of clinical characteristics at baseline for participants and carers 
 Placebo 
N=111 
Sertraline 
N= 107 
Mirtazapine 
N=108 
Duration of depression  <1 month 7 (6%) 3 (3%) . 
 1 – 2 months 4 (4%) 6 (6%) 10 (9%) 
 2 -6  months 24 (22%) 18 (17%) 26 (25%) 
 > 6 months 76 (68%) 75 (71%) 70 (66%) 
     
Severity of depression CSDD 8-11 43 (39) 45 (42) 54 (50) 
 CSDD 12+ 68 (61) 62 (58) 54 (50) 
     
Dementia vascularitya 2.1 (1.3) 2.2 (1.3) 2.2 (1.3) 
Carer rated 
Higher scores indicate a better outcome 
Participant SF-12 103 101 96 
    Physical component (0-100) 43.2 (10.6) 45.2 (11.2) 44.9 (12.4) 
    Mental Health (0-100) 50.1 (11.8) 47.9 (11.1) 46.1 (12.5) 
Participant generic quality of life 
EuroQOL VAS (0-100) 
109 
52.3 (21.1) 
106 
53.8 (19.6) 
105 
51.9 (22.4) 
Lower scores indicate a better outcome 
Participant depression  
CSDD (0-38) 
111 
13.6 (5.2) 
107 
12.8 (3.6) 
108 
12.5 (3.7) 
Participant activity limitation  
BADL (0-60) 
111 
18.2 (11.1) 
106 
16.6 (11.2) 
107 
18.4 (10.9) 
Participant quality of life 
DEMQOL Proxy (31-124) 
91 
88.4 (15.3) 
97 
86.5 (15.6) 
91 
86.9 (13.1) 
Carer mental health 
GHQ-12 (0-36) 
105 
12.6 (5.1) 
103 
12.5 (4.9) 
98 
13.0 (5.9) 
Carer burden 
Zarit (0-88) 
87 
27.2 (16.6) 
93 
27.8 (14.7) 
91 
26.1 (16.0) 
Participant Neuropsychiatric symptoms 
NPI (0-144) 
106 
30.2 (17.6) 
104 
26.9 (16.8) 
108 
29.9 (20.9) 
Participant rated 
Higher scores indicate a better outcome 
Participant cognition 
Standardised MMSE (0-30) 
82 
18.2 (7.4) 
79 
18.5 (6.7) 
90 
17.6 (6.0) 
Participant generic quality of life EuroQOL 
VAS (0-100) 
92 
60.3 (24.1) 
86 
66.6 (17.8) 
91 
66.9 (18.5) 
Lower scores indicate a better outcome 
Participant generic quality of life 
DEMQOL (28-112) 
87 
83.7 (17.2) 
82 
82.5 (14.3) 
91 
85.1 (12.8) 
Data are mean (sd) or number (%) unless stated otherwise 
Frequencies given above summary statistics  
a
modified Hachinski index 
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Table 3: Primary outcomes of research worker rated CSDD score  
 CSDD Score  
 Placebo  Sertraline Mirtazapine 
Baseline mean (sd) 13.6 (5.2); n=111 12.8 (3.6); n =107 12.5 (3.7):n=108 
Week 13 mean (sd) 7.8 (4.1): n= 95 8.6 (4.9): n=78 7.9 (5.0): n= 85 
Week 39 mean (sd) 8.5 (5.5): n=82 8.6 (5.5): n=68 7.7 (6.2): n= 76 
    
Mean difference from placebo(SE) 
(95% CI)  
P-value; n  
   
13 weeks - 1.17 (0.72) 
(-0.23 to 2.58) 
0.10; n=173 
 
0.01 (0.70) 
(-1.37 to 1.38) 
0.99; n=180 
39 weeks  - 0.38 (0.76) 
(-1.12 to 1.87) 
0.63; n=150 
-0.67 (0.74) 
(-2.12 to 0.79) 
0.37; n=158) 
    
Mean difference From mirtazapine 
(95% CI) 
P-value; n 
   
13 weeks - 1.16 (0.72) 
(-0.25 to 2.57) 
0.11; n=163 
- 
39 weeks  - 1.04 (0.76) 
(-0.48 to 2.56) 
0.18; n=144 
- 
Data are mean scores (sd) or n (%), unless otherwise stated. Comparisons of the differences are 
made at 13 and 39 weeks from the final adjusted linear mixed model.  
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Figure 2: CSDD scores by treatment group, unadjusted means  with 95% CI (a lower CSDD 
score means less depressive symptoms).  
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Table 4: Effect of the medications compared with placebo and between themselves on 
secondary participant outcomes and depression severity   
 
  Week 13   Week 39   
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Cognition 
MMSE 
Coeff (SE) 
95% CI  
(p value) 
-0.22 (0.65) 
-1.50 to 1.05 
(0.73) 
-0.27 (0.61) 
-1.48 to 0.94 
(0.66) 
0.05 (0.64) 
-1.21 to 1.31 
(0.94) 
-0.55 (0.68) 
-1.89 to 0.79 
(0.42) 
-1.71 (0.67) 
-2.48 to 0.14 
(0.08) 
0.62 (0.69) 
-0.73 to 1.97 
(0.37) 
Activity 
limitation 
BADL 
Coeff (SE) 
95% CI  
(p value) 
1.40 (1.26) 
-1.07 to 3.88 
(0.27) 
-0.04 (1.23) 
-2.44 to 2.36) 
(0.97) 
1.44 (1.30) 
-1.10 to 3.99 
(0.27) 
1.63 (1.35) 
-1.01 to 4.27 
(0.26) 
1.19 (1.30) 
-1.37 to 3.75 
(0.36) 
0.44 (1.38) 
-2.26 to 3.14 
(0.75) 
Behaviour 
Problems 
NPI 
Coeff (SE) 
95% CI  
(p value) 
2.72 (2.41) 
-2.01 to 7.45 
(0.26) 
-3.56 (2.30) 
-8.07 to 0.96 
(0.12) 
6.28 (2.42) 
1.53 to 11.03 
(0.010) 
2.02 (2.53) 
-2.94 to 6.97 
(0.43) 
-1.51 (2.42) 
-6.25 to 3.24 
(0.53) 
3.53 (2.53) 
-1.44 to 8.49 
(0.164) 
Depression severity       
 low CSDD 
score 
8-11 
Coeff (SE) 
95% CI  
(p value 
1.12 (1.01) 
-0.85 to 3.10 
(0.26) 
-0.30 (0.98) 
-2.21 to 1.61 
(0.76) 
1.43 (0.99) 
-0.51 to 3.36 
(0.15) 
0.33 (1.04) 
-1.72 to 2.37 
(0.76) 
-0.99 (1.02) 
-2.98 to 1.00 
(0.33) 
1.31 (1.04) 
-0.72 to 3.34 
(0.20) 
 high CSDD 
score 
12+ 
Coeff (SE) 
95% CI  
(p value 
1.18 (0.91) 
-0.60 to 2.96 
(0.34) 
0.27 (0.89) 
-1.47 to 2.01 
(0.76) 
0.91 (0.91) 
-0.95 to 2.77 
(0.34) 
0.38 (0.94) 
-1.47 to 2.23 
0.69 
-0.41 (0.91) 
-2..20 to 1.37 
0.65 
0.0.80 (0.97) 
-1.10 to 2.69 
0.41 
Life quality  
DEMQOL 
Coeff (SE) 
95% CI  
(p value) 
0.30 (1.89) 
-3.40 to 4.01 
(0.87) 
-0.06 (1.76) 
-3.52 to 3.39 
(0.97) 
0.37 (1.89) 
-3.52 to 3.39 
(0.85) 
-1.76 (2.04) 
-5.75 to 2.23 
(0.39) 
-0.03 (1.92) 
-3.80 to 3.75 
(0.99) 
-1.74 (2.07) 
-5.79 to 2.32 
(0.40) 
Life quality 
DEMQOL-
Proxy 
Coeff (SE) 
95% CI  
(p value) 
-1.98 (2.14) 
-6.16 to 2.21 
(0.36) 
3.13 (2.15) 
-1.09 to 7.35 
(0.15) 
-5.11 (2.22) 
-9.45 to -0.76 
(0.021) 
2.69 (2.28) 
-1.77 to 7.15 
(0.24) 
3.69 (2.28) 
-0.77 to 8.16 
(0.11) 
-1.00 (2.35) 
-5.61 to 3.60 
(0.67) 
Life quality 
Self-rated  
EQ5D 
Coeff (SE) 
95% CI  
(p value) 
-3.44 (3.78) 
-10.86 to 3.98  
(0.36) 
2.00 (3.67) 
-5.18 to 9.19 
(0.59) 
-5.44 (3.72) 
-5.18 to 9.19 
(0.14) 
-4.34 (4.19) 
-12.56 to 3.88 
(0.30) 
-1.18 (4.12) 
-9.25 to 6.89 
(0.78) 
-3.16 (4.21) 
-9.25 to 6.89 
(0.45) 
Life quality 
Carer-rated 
EQ5D 
Coeff (SE) 
95% CI  
(p value) 
0.61 (3.05) 
-5.38 to 6.59 
(0.84) 
3.62 (3.03) 
-2.31 to 9.55 
(0.23) 
-3.02 (3.17) 
-9.23 to 3.20 
(0.34) 
-0.27 (3.32) 
-6.77 to 6.24 
(0.94) 
-1.11 (3.23) 
-7.44 to 5.21 
(0.73) 
0.85 (3.42) 
-5.86 to 7.56 
(0.80) 
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Table 4: Effect of the medications compared with placebo and between themselves on 
secondary carer outcomes                                                                                                                                                                                                                                                                                                                                                                 
 
  Week 13   Week 39   
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Carer 
burden 
Zarit 
Coeff (SE) 
95% CI  
(p value) 
-0.50 (1.93) 
-4.28 to 3.27 
(0.80) 
-1.14 (1.83) 
-4.93 to 0.65 
(0.56) 
0.64 (1.98) 
-3.23 to 4.51 
(0.75) 
-0.09 (2.07) 
-4.15 to 3.98 
(0.97) 
-2.80 (2.14) 
-6.99 to 1.38 
(0.19) 
2.71 (2.13) 
-1.45 to 6.88 
(0.20) 
Carer 
mental 
health GHQ 
Coeff (SE) 
95% CI  
(p value) 
1.47 (0.72) 
0.06 to 2.89 
(0.042) 
-0.57 (1.23) 
-0.84 to 1.98 
(0.43) 
0.90 (0.75) 
-0.56 to 2.37 
(0.23) 
0.43 (0.77) 
-1.09 to 1.95 
(0.58) 
-0.61 (0.77) 
-2.12 to 0.90 
(0.43) 
1.04 (0.80) 
-0.53 to 2.61 
(0.20) 
Life quality 
SF-12 PCS 
physical 
Coeff (SE) 
95% CI  
(p value) 
1.28 (1.40) 
-1.48 to 4.03 
(0.36) 
-0.53 (1.39) 
-2.20 to 3.26 
(0.70) 
0.75 (1.45) 
-2.10 to 3.59 
(0.61) 
-1.68 (1.48) 
-4.58 to 1.22 
(0.26) 
0.02 (1.46) 
-2.84 to 2.88 
(0.99) 
-1.70 (1.53) 
-2.84 to 2.88 
(0.27) 
Life quality 
SF-12 MCS 
Mental 
Coeff (SE) 
95% CI  
(p value) 
-2.99 (1.47) 
-5.87 to -0.11 
(0.042) 
0.52 (1.45) 
-2.31 to 3.36 
(0.72) 
-3.52 (1.52) 
-6.50 to -0.54 
(0.021) 
0.09 (1.54) 
-2.94 to 3.11 
(0.96) 
-0.31 (1.51) 
-3.28 to 2.66 
(0.84) 
0.40 (1.60) 
-2.74 to 3.54 
(0.80) 
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Table 5: Adverse reactions (definite, probable, and possibly related) by study group 
 
Treatment Group  
Classification placebo 
(events) 
sertraline 
(events) 
mirtazapine 
(events) 
Total Events 
Psychological 10 (22) 9 (18) 24 (44) 53 (84) 
Neurological 8 (9) 16 (25) 18 (21) 42 (55) 
Gastrointestinal 7 (7) 20 (24) 11 (13) 38 (44) 
Other 2 (2) 5 (5) 3 (3) 10 (10) 
Genitourinary 4 (4) 3 (3) 2 (3) 9 (10) 
Musculoskeletal 2 (3) 3 (3) 3 (3) 8 (9) 
Dermatological  3 (4) 3 (3) 2 (2) 8 (9) 
Respiratory 2 (2) 1 (1) 2 (2) 5 (5) 
Cardiovascular 1 (1) 0 (0) 2 (4) 3 (5) 
Infection 1 (1) 1 (1) 1 (1) 3 (3) 
ENT 2 (2) 1 (1) 0 (0) 3 (3) 
Haematological  1 (1)  1 (1) 0 (0) 2 (2) 
Endocrine  0 (0) 1 (1) 0 (0) 1 (1) 
Total**  29 (58) 46 (86) 44 (96) 119 (240) 
**Total number of participants reporting events (note possible to report more than one category of 
events)  
 
 
 
 
 
